Tel: 01789 267520

CK-2127107 / reldesemtiv (Cytokinetics) Updates

CK-2127107 / reldesemtiv is a drug able to increase the force generated by skeletal muscle and delay the onset and extent of muscle fatigue. Cytokinetics, the pharmaceutical company developing CK-2127107 / reldesemtiv, recently announced that it is starting to enrol individuals with SMA Types 2, 3 or 4 in their phase 2 clinical trial in North America, where the drug was granted Orphan Drug status in May 2017.

Clinical Trials Now
 

2018

Cytokinetics Release CK-2127107 Phase II Clinical Trial Data
 

2017

CYTOKINETICS DRUG AWARDED ORPHAN DRUG DESIGNATION IN THE US

Cytokinetics initiates second cohort in Phase 2 Trial of CK-2127107


2016

CYTOKINETICS INITIATES PHASE II TRIAL OF POTENTIAL SMA DRUG